Company Overview of AstraZeneca Canada Inc.
AstraZeneca Canada Inc. operates as a biopharmaceutical company that engages in discovering, developing, manufacturing, marketing, and selling prescription medicines in Canada. It focuses on various therapeutic areas, such as cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory. The company was founded in 1999 and is based in Mississauga, Canada. Astrazeneca Canada Inc. operates as a subsidiary of AstraZeneca PLC.
1004 Middlegate Road
Mississauga, ON L4Y 1M4
Founded in 1999
Key Executives for AstraZeneca Canada Inc.
Chief Executive Officer and President
Chief Financial Officer and Vice President of Finance & Information Systems
Vice President of Human Resources & Communications
Vice President of Strategy and Future Portfolio
Compensation as of Fiscal Year 2015.
AstraZeneca Canada Inc. Key Developments
AstraZeneca Canada Announces Availability of DUAKLIR GENUAIR in Canada for Treatment of Chronic Obstructive Pulmonary Disease
Oct 29 15
AstraZeneca Canada announced that DUAKLIR GENUAIR (aclidinium bromide/formoterol fumarate dihydrate 400/12 µg) is now available in Canada for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. DUAKLIR offers a unique combination of a long-acting muscarinic antagonist (LAMA), aclidinium bromide and fast long acting beta2-agonist (LABA), formoterol fumarate, administered through the GENUAIR device. Approximately 90% of COPD patients experience symptoms such as breathlessness and coughing during at least one part of the day, and as many as 50% experience symptoms around-the-clock. Research has shown that the GENUAIR device is preferred by patients when compared to other devices commonly used for COPD. The inhaler is a pre-loaded, multi-dose dry powder inhaler (DPI) that combines positive feedback mechanisms with the DUAKLIR treatment, which relaxes the muscles of the airways, helping to keep them open, allowing the patient to breathe more easily. By controlling the frequency of daily respiratory symptoms, DUAKLIR GENUAIR can help alleviate patient anxiety and stress related to dosing and symptom management. The device includes two physical mechanisms—a 'click' sound and a colour indicator change, which help reassure patients that their twice-a-day dosages are administered correctly.
AstraZeneca Canada Inc. Launches New FluMist Quadrivalent Flu Vaccine
Oct 26 15
AstraZeneca Canada Inc. announced the approval and availability of FluMist Quadrivalent (FluMist), the only needle-free flu vaccine available in Canada that protects against two A strains of the flu, and for the first time, two B strains.2 FluMist has been shown to be 48% more effective in children ages two to 17 than the traditional flu shot across all strains. FluMist addresses the growing issue of mismatched influenza strains. By adding a second B virus to the traditional trivalent vaccine, the likelihood of matching the major circulating B strain increases. In fact, Canada'sNational Advisory Committee on Immunization (NACI) recommends the use of a quadrivalent flu vaccine for the 2015-2016 flu season. FluMist, a Live Attenuated Influenza Vaccine (LAIV), is administered through the nose, where the flu virus typically enters the body. This method closely mimics natural infection which contributes to its superior efficacy when compared to the traditional flu shot. NACI also recommends a LAIV vaccine like FluMist for children aged two to 17 compared to a traditional flu shot. FluMist is available through nearly all provincial and territorial immunization programs. Each flu season, 3.5 to 7 million Canadians (10% to 20% of the population) will be infected with the flu, and more than 12,000 Canadians are expected to visit the hospital because of the flu and related illnesses. By vaccinating each flu season, Canadians who cannot receive a flu vaccine including infants, seniors and those with compromised or fragile immune systems may also be protected through herd immunity. Herd immunity is important especially in schools and among children, in senior or long-term care facilities and in those aged 65 and older.
AstraZeneca PLC Announces Appointment of Ed Dybka as President and CEO of AstraZeneca Canada Inc
Jan 30 15
AstraZeneca PLC announced the appointment of Ed Dybka as President and CEO of AstraZeneca Canada Inc., effective January 1, 2015. Mr. Dybka has more than 25 years of experience in the Canadian pharmaceutical industry. Mr. Dybka is currently a Director on the Board of Life Sciences Ontario.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|